Relay Therapeutics to participate in upcoming healthcare conferences; webcasts available for live viewing and replay.
Quiver AI Summary
Relay Therapeutics, Inc. announced its participation in two upcoming fireside chats during September 2026, including the Wells Fargo Healthcare Conference on September 8 and the Morgan Stanley Global Healthcare Conference on September 16. The events will be webcast live and can be accessed through the company's website. Relay Therapeutics is focused on developing precision medicine for cancer and genetic diseases, utilizing its Dynamo® platform to tackle challenging protein targets. Its leading candidate, zovegalisib, is currently in Phase 3 trials for HR+/HER2- metastatic breast cancer and is also being explored for various genetic diseases like PI3Kα-driven vascular anomalies, alongside ongoing programs for other conditions. The company aims to provide potentially transformative therapies for patients in need.
Potential Positives
- Participation in high-profile healthcare conferences, which increases visibility and credibility within the industry.
- The company is advancing its lead clinical asset, zovegalisib, into Phase 3 trials, indicating significant progress in its development pipeline.
- Focus on innovative therapies for cancer and genetic diseases highlights the company's commitment to addressing unmet medical needs.
Potential Negatives
- The press release does not provide any updates on the progress or status of zovegalisib in its Phase 3 trial, which may raise concerns among investors about the therapy's development.
- There is no information regarding any recent partnerships, collaborations, or funding efforts, which could indicate potential challenges in securing resources for ongoing or future projects.
- While the press release outlines participation in upcoming events, it fails to mention any significant advancements or milestones achieved by the company, potentially signaling stagnation in development efforts.
FAQ
When are Relay Therapeutics' upcoming fireside chats?
Relay Therapeutics will participate in fireside chats on September 8, 2026, and September 16, 2026.
How can I access the fireside chats?
The fireside chats will be webcast live on Relay Therapeutics' website under the Events section.
What is Relay Therapeutics focused on developing?
Relay Therapeutics develops precise therapies for patients with cancer and genetic diseases using their Dynamo® platform.
What is zovegalisib?
Zovegalisib is Relay Therapeutics' lead asset, a PI3Kα inhibitor currently in Phase 3 trials for metastatic breast cancer.
Where can I find more information about Relay Therapeutics?
For more information, visit Relay Therapeutics' website at www.relaytx.com or follow them on LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RLAY Insider Trading Activity
$RLAY insiders have traded $RLAY stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RLAY stock by insiders over the last 6 months:
- PAULING (CAYMAN) LTD SVF sold 6,000,000 shares for an estimated $116,399,999
- THOMAS CATINAZZO (Chief Financial Officer) has made 0 purchases and 11 sales selling 262,262 shares for an estimated $4,213,095.
- DONALD A BERGSTROM (President, R&D) has made 0 purchases and 4 sales selling 105,843 shares for an estimated $1,808,840.
- PETER RAHMER (See remarks) has made 0 purchases and 4 sales selling 56,009 shares for an estimated $1,069,852.
- SANJIV PATEL (President and CEO) sold 48,199 shares for an estimated $943,736
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RLAY Hedge Fund Activity
We have seen 171 institutional investors add shares of $RLAY stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 16,414,682 shares (+444.2%) to their portfolio in Q2 2026, for an estimated $307,118,700
- POINT72 ASSET MANAGEMENT, L.P. removed 13,859,172 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $137,898,761
- PRICE T ROWE ASSOCIATES INC /MD/ added 5,783,569 shares (+300.5%) to their portfolio in Q2 2026, for an estimated $108,210,575
- COMMODORE CAPITAL LP removed 5,000,000 shares (-29.4%) from their portfolio in Q2 2026, for an estimated $93,550,000
- PERCEPTIVE ADVISORS LLC added 4,355,046 shares (+44.7%) to their portfolio in Q2 2026, for an estimated $81,482,910
- ALLIANCEBERNSTEIN L.P. added 3,950,349 shares (+2719.7%) to their portfolio in Q2 2026, for an estimated $73,911,029
- STATE STREET CORP added 3,891,836 shares (+62.4%) to their portfolio in Q2 2026, for an estimated $72,816,251
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RLAY Price Targets
Multiple analysts have issued price targets for $RLAY recently. We have seen 10 analysts offer price targets for $RLAY in the last 6 months, with a median target of $24.0.
Here are some recent targets:
- Priyanka Grover from JP Morgan set a target price of $28.0 on 07/08/2026
- Brad Canino from Guggenheim set a target price of $26.0 on 05/26/2026
- Robert Burns from HC Wainwright & Co. set a target price of $28.0 on 05/26/2026
- Etzer Darout from Barclays set a target price of $27.0 on 05/20/2026
- Silvan Turkcan from Citizens set a target price of $21.0 on 05/20/2026
- Dane Leone from Raymond James set a target price of $26.0 on 05/19/2026
- Matthew Biegler from Oppenheimer set a target price of $18.0 on 04/28/2026
Full Release
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
- 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET
-
Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 at 9:15 a.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations . An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo ® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn .
Contact:
Mitch Maisel
[email protected]
Media:
Katie Engleman
1AB
919-333-7722
[email protected]
